RxDoctor Payments Data

Evangeline Hillegass, MD

Family Medicine · New Paris, PANPI 1518494509

Payments from drug & device makers

$10,542in general payments, 2019–2025

Across 670 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$789
  • AstraZeneca$619
  • GSK$346
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$10,542100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)123$1,748
Novo Nordisk70$1,096
Pfizer83$1,090
Lilly USA, LLC56$789
AstraZeneca28$619
GSK24$346
Abbott18$287
Otsuka America Pharmaceutical, Inc.16$281
Dexcom, Inc.16$266
Merck16$235
Boston Scientific7$215
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$188
Boehringer Ingelheim12$183
Corcept Therapeutics11$177
Astellas Pharma US Inc10$177
Amgen12$174
Biohaven Pharmaceutical Holding Company Ltd.13$155
Exact Sciences9$153
Amarin Pharma, Inc.9$150
Daiichi Sankyo Inc.7$141
Novartis8$137
Kowa Pharmaceuticals America, Inc.8$135
Ardelyx, Inc.6$131
Sanofi-aventis U.S. LLC9$130
Axsome Therapeutics, Inc.7$124
E.r. Squibb & Sons, L.L.C.6$123
Viatris Specialty LLC6$112
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$108
Mylan Specialty L.p.6$92
Phathom Pharmaceuticals, Inc.7$91
Verona Pharma, Inc.4$89
Sumitomo Pharma America, Inc.4$87
Tactile Systems Technology Inc4$81
Takeda Pharmaceuticals U.S.A., Inc.4$69
Lundbeck LLC3$51
Azurity Pharmaceuticals, Inc.3$43
Teva Pharmaceuticals USA, Inc.3$40
Tandem Diabetes Care, Inc.2$35
Bayer2$32
Biohaven Pharmaceuticals, Inc.2$32
Johnson & Johnson2$29
Philips North America LLC2$29
Medtronic(2 entities)2$25
Genentech USA, Inc.1$25
Sonex Health, Inc.1$24
Paratek Pharmaceuticals, Inc.1$23
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$21
Grifols USA, LLC1$20
Neurelis, Inc.1$19
UCB, Inc.1$17
Arbor Pharmaceuticals, Inc.1$17
Sanofi Pasteur Inc.1$15
SK Life Science, Inc.1$14
Scilex Pharmaceuticals Inc.1$14
Electromed, Inc.1$14
Esperion Therapeutics, Inc.1$13
Biogen1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,542 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$1,735
Medicare patients
89
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$137,549
OzempicSemaglutide90$119,674
JardianceEmpagliflozin76$89,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter112$85,418
EliquisApixaban84$70,204
Soliqua 100-33Insulin Glargine/Lixisenatide42$58,943
FarxigaDapagliflozin Propanediol53$52,133
XareltoRivaroxaban32$35,015
TrulicityDulaglutide26$33,916
VraylarCariprazine Hcl21$30,033
LinzessLinaclotide17$22,219
TradjentaLinagliptin29$20,176
Repatha SyringeEvolocumab25$19,755
EntrestoSacubitril/Valsartan25$16,976
Repatha SureclickEvolocumab24$12,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$789$171,465129 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat$183$128,931135 claims
Novo NordiskOzempic$1,096$119,67490 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$346$98,081135 claims
PfizerEliquis$1,090$70,20484 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$130$58,94342 claims
AbbVieVraylar, Linzess, Synthroid$1,748$56,368115 claims
AstraZenecaFarxiga$619$52,13353 claims
Johnson & JohnsonXarelto$29$35,01532 claims
NovartisEntresto$137$16,97625 claims
MerckJanuvia$235$9,94014 claims
Astellas Pharma US IncMyrbetriq$177$9,61319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in New Paris

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →